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Abstract 
Effectiveness of Continuous Glucose Monitoring in Children, Adolescents and Young Adults 
with Poorly Controlled Type 1 Diabetes 
 




Type 1 diabetes is the second most common chronic illness seen in children.  Children, 
adolescents and young adults with type 1 diabetes are provided care in programs with diabetes 
educators, nurses, nurse practitioners, physicians, dietitians, and many other specialists.  Even 
though children, adolescents and young adults receive care from many providers, their diabetes 
is often not in good control.  In the last 10 years a new device called a continuous glucose 
monitor has been developed for use with people with diabetes.  This new device documents the 
blood sugar levels in people with diabetes between finger stick blood sugar tests.   
Objectives 
This study utilized a newly developed investigational continuous glucose monitoring device in 
children, adolescents and young adults ages 7-21 who had very high blood sugars and a 
hemoglobin A1c of 9% or greater.  The rationale was that if the participants could see their blood 
sugars in between regular testing, it would help them to lower their blood sugars. The study used 
the Family Approach to Diabetes Management model to improve adherence to wearing the CGM 
monitor.  The primary outcome of the study was to improve HbA1c by at least 0.5%.  Secondary 
outcomes of the study included: adherence to wearing the continuous glucose monitor, adherence 
to blood sugar testing, decrease in hypoglycemia, and change in quality of life indicators. 
Design 
This study used a prospective, one group, pre and post-test pre experimental design with a 
convenience sample of patients. The 12-week intervention tested the efficacy of a newly 
developed continuous glucose monitor on glycemic control.  Participants were seen every four 
weeks during the study.  At the baseline visit, demographic data were collected and participants 
completed the Quality of Life for Youth form.  Patients and families were taught to use the 
continuous glucose monitor, and the basic concepts of the Family Approach to Diabetes 
Management Model.  Baseline HgA1c levels were determined as well as reported and actual 
frequency of blood testing was determined. Data collected at the subsequent visits included 
downloads from of the continuous glucose monitor, home finger stick blood glucose monitor and 
completion of a qualitative interview about experiences with the monitor use. In addition, data 
collected at the final study visit included collection of HbA1cs and completion of the Quality of 
Life for Youth forms. 
Subjects 
Thirty-three subjects enrolled in the study.  Twenty-one (63.6%) completed the final study visit 
at 12 weeks.  The mean age of the subjects was 15.57 years with a range of 11 to 20 years.  Of 
the 21 that finished the study, 47.6% were male and 52.4% were female. 
Results 
There was a clinically and statistically significant improvement in HbA1c from baseline by 
1.1095% (SD=1.9321) p=0.016. Fifteen of the participants (71.4%) had an improvement of 
greater than 0.5% in HbA1c.  Participants wore the CGM monitor a mean of 51.1429 (SD  
=20.68543) days with a range of 21 to 81 days. For this study, wearing the monitor any part of 
the day was counted as one day.  The participants wore the monitor a mean of 4.262 days a 
week. At the end of the study, two participants were identified as manipulating the CGM device 
and did not provide accurate finger stick blood glucoses to calibrate the monitor.  The change in 
HbA1c was recalculated removing these participants from the analysis resulting in, a mean 
improvement of 1.4579% (SD=1.6711) p=0.001.  While there were no significant differences in 
quality of life among the six subscales evaluated, there was a trend in improvement of areas of 
symptoms, treatment, parental issues, worry, and health.  Data derived from qualitative 
interviews demonstrated an improved attitude among the participants and improved parent child 
interaction. 
Conclusion 
Continuous glucose monitoring with the Family Approach to Diabetes Management model was 
effective in improving glycemic control with children, adolescents and young adults with poorly 
controlled diabetes.
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Effectiveness of Continuous Glucose Monitoring in Children, Adolescents and Young Adults 
with Poorly Controlled Type 1 Diabetes 
CHAPTER 1 INTRODUCTION 
Background and Significance  
Background 
Type 1 diabetes is the second most common chronic childhood illness, and it is estimated 
that there are 215,000 children under the age of 20 with type 1 diabetes in the United States 
(Centers for Disease Control and Prevention, 2011). Type 1 diabetes is a manageable lifelong 
chronic disease, and if well controlled, a person can live a long and productive life.  
Unfortunately, in spite of aggressive diabetes management strategies, a large majority of 
children, adolescents and young adults with diabetes are not adequately controlled (Silverstein et 
al., 2005).  Poorly controlled diabetes can lead to a number of chronic complications which can 
ultimately lead to blindness, kidney failure, nerve damage, and heart disease (Sperling, 2002).  
Continuous glucose monitoring (CGM) has been shown to improve glycemic control in children, 
adolescents and young adults when worn 6 or more days per week (Juvenile Diabetes Research 
Foundation Continuous Glucose Monitoring Study Group, 2009).  This study will evaluate the 
effectiveness of CGM in children, adolescents and young adults with poorly controlled diabetes 
in improving glycemic control, adherence to the diabetes treatment regimen, and quality of life.  
The study tested a new investigational sensor that can be worn for up to six days a week. 
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Significance 
Adolescents are in a time of transition from relying on parents for total care to complete 
self-care as an adult. Teenage rebellion can complicate the adolescent’s ability to be successful at 
completing all of the tasks associated with the diabetes management regimen.  In the past, 
adolescents who did not adhere to adequate self-care behaviors have classically been labeled as 
non-compliant or difficult to manage.   
If optimal care and adherence is not achieved, the patient is at higher risk for developing 
both acute and chronic complications of diabetes (Schilling, Knafl, & Grey, 2006).   Acute 
complications of diabetes can include diabetic keto-acidosis (DKA) and hypoglycemia.  While 
DKA has a high rate of resolution, approximately 1 in 100 children with DKA will have a poor 
outcome including death or permanent disability (Sperling, 2002).  Severe hypoglycemia can 
also have potentially grave outcomes (Sperling, 2002).  Chronic complications of poorly 
controlled diabetes can include: retinopathy, neuropathy, nephropathy, heart disease, and 
hypertension (Sperling, 2002).  While long-term complications may take many years to develop, 
once present, they are irreversible and all have permanent lifelong consequences (Sperling, 
2002).  The goals for glycemic control in the population is an HbA1c level <8% (Silverstein et 
al., 2005).  
Several factors can be associated with increasing difficulty in managing adolescent 
diabetes.  Puberty can cause a significant increase in insulin requirements (Sperling, 2002).  
Widely varying schedules can necessitate the need for flexible insulin regimens to achieve 
glycemic control.  Teenage rebellion can complicate an adolescent’s ability to be successful at 
completing all of the tasks associated with the diabetes management regimen.  Because the needs 
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of children, adolescents and young adults with type 1 diabetes are complex, their self-care is best 
facilitated by a multidisciplinary team that can address all of the health and psychosocial needs 
of children, adolescents and young adults (Sperling, 2002).  
Theoretical Framework 
Identification of Clinical Problem 
Children, adolescents and young adults with type 1 diabetes present unique challenges 
that complicate the normal growth and development seen at this age.  Diabetes management 
including blood sugar testing, insulin injections, and dietary restrictions complicate the daily 
activities of these groups.  As children grow into adolescents and young adults, these challenges 
continue to be more difficult (Schilling et al., 2006). While a number of educational theories 
exist to address delivery of diabetes education to patients, none address the complexities of 
dealing with children, adolescents and young adults with diabetes and their families as a whole.  
The Family Approach to Diabetes Management was developed from a family therapy model 
specifically designed to address the patient and the family as a whole (Solowiejczyk, 2004). 
Explanation of the Model 
The Family Approach to Diabetes Management   (FADM) model directly addresses the 
problem of poor adherence to diabetes self-care and the family’s integral effect on self-care 
behaviors (Solowiejczyk, 2004).   Tenets of the model are that diabetes is a complex disease 
affecting the whole family, that no other chronic disease places so many burdens on the child, 
adolescent and young adult, and that family function has a direct role on outcomes of metabolic 
control. The FADM model was developed based on the unpublished findings of work done at 
Children’s Hospital of Philadelphia (CHOP) in the 70’s and 80’s using a family therapy 
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approach to chronic care. The author of the model, Solowiejczyk, was a member of the original 
study group.  The staff at CHOP utilized their findings to develop a model that could be applied 
to children, adolescents and young adults with diabetes.  Unfortunately, these initial findings 
were not published, but Solowiejczyk utilized these earlier findings to develop this model.  A 
major factor was identified that led to a higher likelihood of positive outcomes was that positive 
family communication is essential to create behavior patterns that will lead to successful self-
care.  Other major determinants of a positive outcome were the mother’s sense of how supported 
she felt and the ease of getting the family scheduled for education sessions (Solowiejczyk, 2004).   
 Clinical assumptions of the model are based on the following factors: the family’s 
resources, needs and rules affecting the outcomes for the child, and expectations of self-care.  
The patient is the entire family and must be treated as a whole unit.  Responsibility for self-care 
is not an option, it is the expected behavior (Solowiejczyk, 2004).  Parents are the rule makers in 
the home; they control the money, food, clothes, car, and recreational activities.  Because they 
control all of these factors, they need to set expectations for self-care, and also to determine the 
consequences for poor self-care behavior.  Mismanagement of diabetes should be treated the 
same as not doing chores or homework, i.e., you don’t have to like it; you just have to do it.  The 
main thought is children will rise to the highest level they are asked to achieve. 
Theory Application  
The populations for the capstone project were children, adolescents and young adults 
ages 7-21 with poorly controlled diabetes (HbA1c level at 9% or higher).  The intervention 
utilizes continuous glucose monitoring to increase awareness of blood sugar patterns so that the 
patient and family could have a greater understanding of the implications of the diabetes self-
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management behaviors.   In addition to providing a greater understanding of how the person’s 
behaviors affects his or her diabetes self-care, the CGM device gives instant feedback in the form 
of a real time trend of the individual’s blood sugar values. The family can use these values to 
look back at the individual’s day and evaluate how well he or she did in managing the diabetes 
that day.  The patient and family can utilize the findings to make adjustments to the insulin 
regimen utilizing pattern management to adjust the insulin doses to improve the glycemic 
control.   
Diabetes affects the family as a whole.  In a large majority of cases where the 
child/adolescent/young adult is in poor glycemic control, the patient and parent interactions 
focus on negative feedback from the parent and are often seen as nagging.  For example, if the 
individual has a high blood sugar, the parent and their child/adolescent/young adult may be in a 
disagreement because the blood sugar is elevated instead of utilizing this moment as a learning 
point for the dyad.  For example, if the patient did not take his or her insulin, the parent can put a 
plan in place to help make sure someone helps him or her get the proper dose of insulin at the 
right time.  If the blood sugar is elevated because the patient did not calculate the proper dose of 
insulin, the parent can review each of the foods that the patient commonly eats and generate or 
devise a quick list of common foods and amount of insulin based on each usual serving he or she 
eats.  The goal of the model is to refocus the family to positive communication patterns, to set 
reasonable and attainable goals for self-care measures, and to have a plan for consequences of 
undesirable behaviors.   
Past studies have shown that benefit from use of CGM monitors is only obtained when 
the monitor is worn at least 70% of the time (Wilson et al., 2011).  Because the intervention is 
dependent upon the use of the device to be successful, the family was asked to meet together on 
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a regular interval to discuss the diabetes care behaviors and come up with a plan based on how 
the family perceives the patient is doing based on blood sugar patterns.   Initially, the family was 
asked to meet each evening for 5-10 minutes to review the blood sugars on the CGM device. The 
family would then reflect on the pattern of blood sugars and identify problems with particular 
foods or missed insulin doses.  The treatment team asked the family to meet daily until both the 
patient and parent agreed that the individual was doing well with insulin dosing and calculating 
insulin doses based on food consumption.  If the patient was having trouble with dosing of 
insulin or testing the blood sugar and calibrating the sensor, the team would give them strategies 
to improve this behavior, such as the family sitting together each time the patient tested the blood 
sugar, determining the insulin dose together, and supervising or giving the insulin dose.   
Once they were meeting the basics of diabetes care, the family could space these 
meetings out to every three days.  The meetings every three days were used to reinforce self-care 
activities and to review the blood sugars to adjust the insulin doses based on these patterns.  
Once the family was meeting the goals of blood sugar control and self-care activities, they were 
able to space the family meetings out to once a week.  The purpose of this meeting was to review 
the self-care measures and glycemic control.  If the parent found that the patient was not doing 
well, the family meetings needed to be moved back to every three days or even daily.   
In the event that the child/adolescent did not meet the basics of self-care even with daily 
meetings, the parent needed to be willing to implement consequences for poor behaviors.  These 
consequences needed to be age specific and individually tailored.  For example, consequences 
for older adolescents that wanted to learn to drive or be able to drive their parent’s car could be 
the loss of driving privileges for a predetermined amount of time.  For younger adolescents it 
could be tied to money, use of cell phones, computer use or other luxuries that would have a 
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negative impact on the adolescent and improve the self-care behaviors.  The consequence were 
time-limited and appropriate, for example, loss of cell phone use for one week If the behavior 
improved, the patient could get the privilege back the next week. If not, he or she would lose it 
for another week.  The primary purpose for the use of the model was  not only to improve family 
communications, but also to improve diabetes self-care behaviors and ultimately increase the use 
of continuous glucose monitoring.   
Importance/Relevance to Nursing Practice 
Healthcare of children, adolescents and young adults with type 1 diabetes has significant 
implications for nursing practice.  Care is best provided by a multidisciplinary team that includes 
diabetes nurse educators and nurse practitioners.  If optimal care and adherence is not achieved, 
the patient is at higher risk for developing both short and long term complications of diabetes 
(Schilling et al., 2006).   The Family Approach to Diabetes Management (FADM) model is 
directly applicable to the study population and the goals of increasing adherence to tasks 
associated with diabetes self-management (Solowiejczyk, 2004).  This model was developed by 
the Solowiejczyk, utilizing the originally developed concepts from earlier studies that were 
unpublished (Solowiejczyk, 2004).   
Summary 
 The FADM model was designed to treat diabetes in children as a family problem and not 
just a disease of the child.  The model provides a framework to promote family communication 
with the ultimate goal of increasing adherence to diabetes self-care tasks.  A major problem 
identified in children, adolescents and young adults with type 1 diabetes is poor adherence to 
their diabetes care.  This model was used to promote the use of the CGM monitor during the 
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study.  The families were taught at visit one to have regular family meetings based on blood 
sugar goals for the patient. They also developed consequences that the patient and family agreed 
to put into place for unacceptable behaviors related to diabetes care.  The family was encouraged 
to track the use of the model by entering the family meetings into the patient diary. 
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CHAPTER II REVIEW OF THE LITERATURE 
Project Description 
Introduction and Background 
In the past 10 years, continuous glucose monitoring has been developed with the goal of 
improving the outcomes in people with diabetes (Blevins et al., 2010). The standard of diabetes 
care includes traditional diabetes education intervention and management in a multidisciplinary 
setting (Sperling, 2002).  Some data are available on the efficacy of continuous glucose 
monitoring on improving outcomes of diabetes care.  Studies have been conducted to evaluate 
the efficacy of CGM in children, adolescents, and adults with diabetes (Blevins et al., 2010).  
However, a gap exists in the literature as to whether CGM improved HbA1c in children, 
adolescents and young adults with poorly controlled diabetes.  The review of the literature herein 
focused on the following question: In children, adolescents and young adults ages 7-21 with 
poorly controlled type 1 diabetes (HbA1c at 9% or higher) does continuous glucose monitoring 
improve glycemic control as evidenced by HbA1c, adherence to diabetes self-care behaviors, and 
quality of life. 
 
Search Strategy 
A comprehensive search strategy was developed to locate the best evidence for 
effectiveness of continuous glucose monitoring use in children, adolescents and young adults 
with poorly controlled type 1 diabetes. and its effect on lowering HbA1c.  The search included a 
search of: National Guideline Clearinghouse, The Cochrane Library, Academic Search 
Complete, PubMed, and CINAHL. These databases were searched using the key words: 
continuous glucose monitoring, diabetes, children, and adolescents. There was no limit on 
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geographic location, but studies were limited to the last eight years. The search was limited to 
English language and to subjects less than 18 years of age. The initial search that included all of 
the key terms returned 45 articles.  Further searches were completed using combinations of key 
words including continuous glucose monitoring and diabetes, which returned 437 papers.  No 
clinical practice guidelines specifically for use of CGM in children or adolescents were found, 
however an adult guideline with a small pediatric section was identified.  The search was limited 
to articles that were systematic reviews, randomized controlled trials, non-randomized controlled 
trials, and cohort studies that were published from 2005 to 2013.  Snowballing was utilized to 
find further studies, but none were found.  The titles of the 437 papers that were found were 
manually scanned for applicability to the search. Finally, seven studies were included in the 
review, two systematic reviews, and six randomized controlled studies.  These studies were 
included because they had pediatric subjects who utilized the continuous glucose monitor and 
had outcomes relevant to this project. 
Critical Appraisal  
 A critical appraisal of each of the eight articles was completed utilizing appropriate 
appraisal tools.  The systematic reviews were appraised utilizing the Scottish Intercollegiate 
Guideline Network form for systematic reviews.  The six randomized control trials were 
appraised utilizing the SIGN (2012) form for randomized control trials. The first systematic 
review evaluated outcomes of glycemic control in children, adolescents, and adults from six 
studies (Joubert & Reznik, 2011).  All of the six studies focused on the use of insulin pump 
therapy with CGM monitoring and showed improved outcomes of glycemic control compared to 
standard and multiple injection therapy.  Secondary findings of most of the studies showed 
improvement in HbA1c for participants that wore the device more than 70% of the time.  This 
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review is limited in application to this study because the focus is on concurrent use of CGM and 
Continuous Subcutaneous Insulin Infusion (CSII) in adolescents.   
 The other systematic review evaluated a total of 14 studies (Wojciechowski, Ryś, 
Lipowska, Gawęska, & Małecki, 2011).  Eight of these studies were based on current CGM 
systems (worn continuously), which gives the patient instant information.  Six studies were 
based on older retrospective systems for diagnostic intermittent use.  The studies that evaluated 
the current continuous CGM system showed an HbA1c improvement ranging from 0.15-0.43%, 
the average improvement in this group was 0.27%, with the lowering of both groups’ HbA1c by 
0.26% (p < 0.0001) (Wojciechowski, Ryś, Lipowska, Gawęska, & Małecki, 2011).  The authors 
found inconsistencies in ways that hypoglycemia and hyperglycemia were reported making 
secondary analysis of the data difficult.  Due to the variety of ways in which the studies reported 
the ages, the authors were not able to report findings in the 8 to 18 year age range.  These studies 
showed favorable findings for use of CGM when compared to standard finger stick blood sugar 
testing alone.   
 Two of the RCT studies (Battelino et al., 2011; Raccah et al., 2009) evaluated the use of 
CGM in conjunction with insulin pump therapy also known as continuous subcutaneous insulin 
infusion (CSII).  Both studies evaluated children, adolescents and adults.  Each study lasted one 
year and evaluated HbA1cs.  They both compared a group using continuous subcutaneous insulin 
infusion with CGM technology to a control group of patients on injection therapy that were not 
using CGM.  In each of these studies, the CGM group showed improvement in HbA1c by 0.51% 
(p < 0.001) and 0.27% (p = 0.008), respectively over the group on injection therapy that did not 
use the CGM monitor. 
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 The Juvenile Diabetes Research Foundation (JDRF) CGM study group evaluated 322 
adults and children with HbA1c levels ranging from 7-10% in a RCT utilizing CGM 
(Tamborlane et al., 2008).   They found that adults had a significant lowering in HbA1c levels.  
Children ages 8-14 had less hypoglycemia (even though the study was not designed to measure 
hypoglycemia significance), but did not have an improvement in HbA1c levels (p = 0.29).  
Adults (> age 25) that had improvement in HbA1c levels utilized the CGM device six or more 
days per week, those ages 15 to 24 utilized the device 30% of the time and children ages 8 to 14, 
50% of the time.  Strength of the study was that a large number of adults were evaluated during 
the study.  The small number of children in the study limited the study, and there was no 
secondary analysis of subsets of the population done to evaluate outcomes based on the amount 
of time that the device was used. 
 The Juvenile Diabetes Research Foundation (JDRF) CGM study group in another study 
evaluated 129 participants ages 8 to 69 years with HbA1c <7.0 %; they compared a treatment 
group that utilized a CGM monitor to a control group that did standard finger stick blood sugar 
testing alone (Beck et al., 2009b).  The investigators evaluated the outcomes at six months for 
each of the groups.  The participants had less time at hypoglycemia compared to the control 
group, but the difference was not statistically significant (p = 0.43).  The investigators found 
reduction in HbA1c, a difference of improvement of 0.34% compared to the control group, 
without worsening of hypoglycemia (p < 0.001). Strengths of the study included the large study 
population and comparable control group.  The weakness of the study was that only patients that 
were very well controlled were sampled, and there was no stratification of HbA1c by ages.   
 The remaining two RCT studies evaluated the use of CGM in patients with type 1 
diabetes that were well-controlled (Battelino et al., 2011; Beck et al., 2009a).  The first study 
Running head: Effectiveness of Continuous Glucose Monitoring 20 
 
evaluated 120 adults and children and showed that both children and adults had improvement of 
HbA1c of 0.27% (p < 0.001) and less hypoglycemia with use of CGM when compared to the 
control group (p < 0.001). The second study also showed that participants had less time spent in 
hypoglycemia compared to the control (p = 0.009) and improved HbA1c levels >/= 0.3% 
(p=<0.001) with CGM use.  This study showed improvement in HbA1c when the device was 
worn 6 or more days a week.  Strengths of the studies included the duration of  26 weeks, and 
they were designed to evaluate hypoglycemia and HbA1c improvement.  A weakness of the 
studies was the difficulty in evaluating outcomes specifically in children based on how the 
patients’ ages were stratified in the data analysis. 
Synthesis   
 All of the studies reviewed evaluated children with diabetes and CGM use.  Two 
systematic reviews and 5 RCTs showed improvement in HbA1c levels with CGM use in children 
and adolescents.  Two RCTs (Battelino et al., 2011; Beck et al., 2009b) showed decreases in 
hypoglycemia with CGM use while improving HbA1c levels. One of the studies (Tamborlane et 
al., 2008) showed no significant improvement in HbA1c levels.  None of the studies evaluated 
the use of CGM in patients with HbA1c > 10%.  These studies show the benefits of CGM in 
children, adolescents, and adults who wore the device 6 days a week or more (Beck et al., 
2009a).  
 One of the systematic reviews found a higher percentage of patients reaching a goal of 
HbA1c with an intervention of continuous glucose monitoring (CGM) and a secondary effect of 
less hypoglycemia (Wojciechowski et al., 2011).  The second systematic review found a 
lowering of HbA1c of 0.5 to1.0% without increased risk of hypoglycemia (Joubert & Reznik, 
2011).  Each of the systematic reviews included studies with both adults and children.  One RCT 
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evaluated factors affecting improved outcome of HbA1c, and found that improved HbA1c was 
seen in patients that wore the sensor >70% of the time (Joubert & Reznik, 2011)).  One RCT 
showed benefit of CGM in adults that wore CGM, but did not show the same results in children 
and adolescents due to their wearing the device less often (Tamborlane et al., 2008).  Two of the 
RCT studies evaluated the outcome of hypoglycemia in groups, both adults and children, that 
were at or close to HbA1c goal and showed less hypoglycemia (Battelino et al., 2011; Beck et 
al., 2009b).  Two RCTs showed improvement in HbA1c when utilizing CGM with concurrent 
initiation of insulin pump therapy (Battelino et al., 2011; Raccah et al., 2009). 
Discussion  
 The literature review identified the need for further research to evaluate the effectiveness 
of CGM on adherence to treatment, and improving HbA1c in children, adolescents and young 
adults with diabetes, especially those with poor diabetes control.  Quality of life is another 
variable that needs to be addressed that was not considered in the studies.  All but one of the 
studies utilizing CGM (Tamborlane et al., 2008) showed statistically significant improvement in 
HbA1c levels, but pediatric participants in this study did not wear the CGM on an almost daily 
basis.  One study found improvement in HbA1c in this population when the CGM was worn 6 or 
more days a week (Beck et al., 2009a).  The proposed study evaluated the short-term use (12 
weeks) of CGM in children, adolescents and young adults with HbA1c levels of 9% or higher.  
The potential benefits of this intervention in improving HbA1c levels are important for this 
population.  While this intervention has been found to improve HbA1c levels in children, 
adolescents and young adults who are at goal of HbA1c or near goal, this was the first study 
undertaken in children, adolescents and young adults with very high HbA1c levels.  
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Conclusion  
 Children, adolescents and young adults with diabetes present unique challenges that are 
not seen in adults.  In addition to everyday challenges of diabetes self-management, normal 
issues observed in growth and development can complicate the self-care regimen.  While 
standard diabetes education has been shown to improve HbA1c levels in general, HbA1c levels 
in at-risk populations have continued to rise in spite of standard diabetes education.  
Improvement of metabolic control in diabetes is important in decreasing the risk of potential 
complications including: retinopathy, nephropathy, neuropathy, and heart disease.  HbA1c 
improvement has been shown to significantly decrease the risk of these complications.   
 A systematic review of the literature has shown that continuous glucose monitoring is 
effective in lowering HbA1c levels.  Further studies need to be completed to verify the 
effectiveness of this intervention in lowering HbA1c levels in children, adolescents and young 
adults with very high HbA1c levels.  Due to the higher costs associated with CGM, long term 
studies need to be done to show the benefits, especially in high-risk populations benefit.  While 
there are no long-term studies to evaluate the decrease in chronic complication of diabetes, short-
term improvement may suggest a decrease in long-term risk of complications. Such studies could 
show benefit to this at-risk population and justify that insurance companies cover this therapy as 
standard of care.  
 
Project Objectives 
The first objective was to improve HbA1c levels in children, adolescents and young 
adults with poorly controlled diabetes by using continuous glucose monitoring.  
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This study was done at WVU Pediatric Endocrinology clinic in Charleston, WV. The 
goal was to recruit 40 patients ages 7-21 with an HbA1c level of 9% or higher. HgA1c was 
measured at baseline and again at a 3-month visit to evaluate the change in HbA1c. The research 
plan included strategies to help the family and participant meet the goals of wearing the 
continuous glucose monitor 6 or more days a week. The goal was to improve HbA1c, thereby 
decreasing risk of long-term risk of complications. A lowering of HbA1c level by 0.5% is 
considered to be clinically significant.   
The second objective was to increase adherence to the diabetes regimen by using 
continuous glucose monitoring.  The team measured adherence to the diabetes regimen at 
baseline and at one, two and three months to evaluate the outcome. The team utilized the Family 
Approach to Diabetes management model to improve the patient’s likelihood of adhering to 
finger stick glucose monitoring. This approach needed to be employed to increase the likelihood 
that the participant would adhere to testing the blood sugar three or more times a day. The 
research plan included strategies to help the family and participant meet the goals of increasing 
blood sugar testing (adherence). The goal was to improve testing to three or more times a day.   
The third objective was to improve quality of life in children, adolescents and young 
adults with poorly controlled diabetes by using continuous glucose monitoring.  
The team measured Quality of Life utilizing the Quality of Life Short form at baseline 
and at three months.  The Family Approach to Diabetes management model was used to improve 
the patient’s likelihood of adhering to the use of the continuous glucose monitor. This approach 
needed to be employed to increase the likelihood that the participant would use the device 6 or 
more days a week, which was shown to improve outcomes in previous studies.  The evaluation 
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of quality of life was a secondary objective of the study.  The research plan included strategies to 
help the family and participant meet the goals of wearing the continuous glucose monitor 6 or 
more days a week. The goal was that it would improve the quality of life for participants.   
The fourth objective was to help the participants deal with the increased pain associated 
with use of the CGM sensor, finger stick blood sugar testing, and insulin injections. 
The goal was to increase the participant’s adherence to the treatment regimen by 
increasing blood sugar testing, insulin injections and use of the CGM six or more days a week. 
The team gave the patient tips for decreasing pain associated with use of diabetes related tasks in 
the form of a handout to identify resources available.  Participants were given lidocaine / 
prilocaine cream at time of entry into the study to be used for pain associated with insertion of 
the CGM sensor. The goal was for participants to have increased blood sugar testing, increased 
self-reporting of insulin injections and use of CGM device 6 or more days a week by download 
at the one month follow up.  
Congruence of Organizations Strategic Plan to Project 
Children, adolescents and young adults with diabetes are seen for regular follow up every 
three months in the pediatric endocrine clinic.  Patients that have HbA1c levels at 10% or greater 
are seen at a more frequent interval of every 4 to 6 weeks.   Several years ago, the organization 
held a high-risk clinic for children with elevated HbA1c levels. The program included diabetes 
educators, a dietitian, and a psychologist.  The program only lasted one year.  The patient show 
rate for the clinic was very low and after the year, the clinic could not be continued.  The WVU 
pediatric endocrine practice currently follows 600 children with diabetes, with a large majority of 
these children being adolescents and young adults.  In the practice, a significant number of these 
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adolescents have HbA1c levels greater than 8% and a number are greater than 10%.  The 
practice has approximately 130 children, adolescents and young adults with HbA1c level at 9% 
or greater.  The clinic is located in the Department of Pediatrics in the WVU School of Medicine, 
Charleston Division.  The organizations mission includes patient care, research and service.  The 
organization is supportive of the project and will allow adequate time and resources to make the 
project successful (Appendix A). 
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CHAPTER III METHODOLOGY 
Project Design 
Evidence Based Project/Intervention Plan 
This practice change project used a prospective, one group, pre and post-test pre 
experimental design, with a convenience sample of patients (Polit, D. F., 2008).   Because this is 
a practice change, there was no control group.  The practice change intended to place 40 
participants on CGM for three months to compare the primary outcome of HbA1c at baseline 
and at 3 months. In addition, quality of life utilizing the Diabetes Quality of Life in Youth Short 
Form (Skinner, Hoey, McGee, & Skovlund, 2006) was to be measured at both time points.  The 
use of the Family Approach to Diabetes Management model was evaluated at each visit by 
reviewing the diary of visits. In addition to these measurements, other indicators of adherence 
including number of blood glucose tests per day and total amount of insulin taken daily (self-
reported) was measured.  The demographic data included age, gender, length of time since 
diagnosis of type 1 diabetes, family support system, family dynamics, and who was the primary 
caregiver (see Appendix B). 
Sample 
A convenience sample of 33 participants was recruited from the WVU Pediatric 
Endocrinology Clinic in Charleston WV.  Participants were ages 9-20 years with type 1 diabetes 
and HbA1c 9% or greater.  Twenty-one of the participants completed the study.  Parents of 
patients under 18 signed a consent form and patients an assent form. Patients over 18 signed a 
consent form.  
To increase the likelihood of participants would return for follow up study visits, the 
study offered an incentive program for each study visit completed.  The incentive was $20 for 
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the baseline visit and for each of the follow-up visits.  These incentives were in the form of Wal-
Mart gift cards.  This was to help offset the costs of travel to participate in the study.   
Procedures/Protocol 
Participants who met inclusion criteria completed consent/assent forms and a baseline 
HbA1c was drawn.  Data for the number of blood sugar tests done daily were obtained from 
blood glucose meter downloads, and the total amount of self -reported insulin taken during the 
day was recorded. The Quality of Life in Diabetes Youth Short Form was administered.  
Participants were then instructed on the use of the Medtronic Guardian CGM device and Enlite 
sensor.  The Guardian CGM system is an FDA approved device that is to be used as an adjunct 
to regular blood sugar testing. The Enlite sensor is a minimally invasive sensor that works with 
the Guardian device to determine the patient’s blood sugar.  The device is investigational and 
does not currently have FDA approval for sale in the US, although the device is approved for use 
in 35 other countries.  The device does not pose a significant risk to the patient, is minimally 
invasive and is used only as a trending device to make insulin adjustments.  The patient needed 
to test his or her blood sugar at least twice a day to calibrate the system in order to get a reading 
on the sensor.  The patients were instructed to test their blood sugars to determine the accurate 
dosing of insulin and any time the CGM monitor identified that they had a low blood sugar (< 
70mg/dL).  The device was initiated in the office.  Follow up visits occurred at 1 and 2 months 
after enrollment. At each follow up visit, the investigators downloaded the meter, CGM device, 
and made insulin adjustments as needed.  Participants then received supplies for the next 4 
weeks.  The final study visit was at the 3 months.  At the final study visit, the investigators 
obtained HbA1c levels, downloaded the blood glucose meter to determine frequency of blood 
sugar tests, obtained self-reported insulin dosing, and re-administered the Quality of Life in 
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Diabetes Youth Short Form.  The diary tracking family meetings utilizing the FAMD model 
were reviewed at each study visit.  After the study was completed, the patients were given their 
CGM system, and the investigators attempted to obtain insurance authorization for sensors for 
continued use of the device. 
Risks 
 The primary goal of the intervention was to lower HbA1c levels, but lowering HbA1c 
carries with it the risk of an increase of hypoglycemic events.   The increased risk is associated 
with improved control and not the actual use of the CGM monitor.  Because previous studies 
have shown less likelihood of hypoglycemia with the use of the CGM device, the potential risks 
of implementing CGM were considered to be minimal.  
 
Primary Outcomes 
 The primary study variables were the change in HbA1c levels. Secondary outcomes 
included adherence to treatment regimen, and quality of life measures.  HbA1c levels were 
determined by point of care testing (POCT) in the clinic.  The HbA1c level was drawn at 
baseline and at three months with a goal of at least 0.5% improvement in control as being 
clinically significant.  The HbA1c levels were done using the Siemens DCA Vantage POCT 
system.  This system has previously been evaluated and determined to meet the guidelines for 
glyco-hemoglobin standardization (Battelino et al., 2011).  HgA1c data were analyzed using a 
paired t-test. Adherence to treatment regimen was evaluated by using data downloaded from the 
participants home blood glucose monitor and from the CGM monitor.  These data were analyzed 
using a repeated measures ANOVA test.  
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The study evaluated adherence to finger-stick blood sugar testing by recording the 
number of blood glucose tests done each day based on the 30-day average from the home meter 
download.  CGM adherence was evaluated by recording the number of hours the patient wore the 
device from the CGM monitor data.  These data were collected at monthly follow up visits and 
analyzed using a repeated measures ANOVA test.   
The CGM downloads were evaluated by the number of hypoglycemic events recorded.  
The number of these events in the patient diary was then compared to the patient diary to 
evaluate the number of hypoglycemic events, duration of hypoglycemic events, and the number 
of hypoglycemic events that required assistance to treat.  
 Quality of life was measured utilizing the Quality of Life in Diabetes Youth Short Form 
(Skinner et al., 2006).  A previous study of 2,077 young people found this tool to be both valid 
and reliable (Skinner et al., 2006).  This is a 22-item form that was developed from an original 
55 question Diabetes Quality of Life Youth Form; the old form was lengthy and redundant.  This 
new form can be completed by the participants in about 5 minutes.  The researchers found a 
statistically significant correlation between the new form and the older lengthy form in all areas 
except impact on activities.  The subscales for form include impact of symptoms related to 
diabetes, impact of treatment, impact of activities, parent issues, worries about diabetes, and 
health perception.  The answers are scored on a likert scale of 0-4 with a higher number meaning 
worse quality of life in that area.  The health perception is scored from 1-4 with a higher number 
being worse.  This form was administered at the initial and three-month final study visit.  The 
Novo Nordisk study group holds the copyright for this form.  There was no charge to use the 
form for the study and data use agreement was in place and approved. A paired t-test was used to 
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analyze the quality of life data.  The Family Approach to Diabetes Management model was 
evaluated by diaries the patients completed for review at each at study visit. 
Conclusion 
Continuous glucose monitoring has the potential to add a valuable tool to treat what has 
traditionally been described as a difficult group of patients.  In spite of comprehensive diabetes 
education and treatment, HbA1c levels continue to rise in this group, and other interventions in 
the past have shown little improvement (Silverstein et al., 2005).  This study evaluated the 
primary outcome of glycemic control.  It also evaluated secondary outcomes including: 
adherence, quality of life and qualitative outcomes. 
Timeline of Project Phases 
Clinical Initiatives Utilizing the Logic Model 
The logic model was revisited and utilized to develop the clinical initiatives, see Table 1.  The 
clinical initiatives were developed for use in the study to evaluate the effectiveness of continuous 
glucose monitoring for children, adolescents and young adults ages 7 to 21 with poorly 
controlled diabetes (HbA1c of 9% or greater). 
Table 1 
Project Timeline  
Item to Be Addressed Specific Plan Timeline Comments 
Obtain grant funding 
for CGM monitor and 
supplies 
Applied for grant 
funding from 
Medtronic diabetes 
and CAMC research 
Grant was secured by 
both agencies in 
December 2012 
Late change in 
protocol required 
additional time with 
IRB to approve the 
use of an 
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institute. investigational device. 
Final grant was 
received from CAMC 
Research Institute to 
cover study costs and 
patient incentives. 
Obtain permission for 
use of Quality of Life 
in Diabetes Youth 
Short Form 
 Email confirming use 
of the form after 
completing of use 
agreement. 
Completed Emailed copyright 
holder to clarify that 
the correct version 
was in the agreement. 
Develop education 
plan for FADM model 
for staff 
Using the FADM 
model, we will 
educate the nursing 
staff on how to use 
the model to educate 
the families when 
teaching them the 
CGM device 
The nursing staff was 
trained in using the 
FADM model during 
the study. 
Needed to educate the 
staff on how to 
educate the family to 
buy into the model for 
success. 
Develop capstone 
plan to present to 
committee 
Plan developed by the 
end of Nursing 793 
Plan completed by 
5/15/2012 
 
Present capstone plan 
to DNP Capstone 
committee 
Present plan to 
committee chair and 
members for approval 
Plan was presented by 
7/15/2012 
 
Submission to IRB WVU IRB in was the 
primary Morgantown 
IRB, with secondary 
approval needed from 
Charleston IRB  
November 30, 2012 There was delay 
related to the use of 
an investigational 
device and the 
requirement to get 
approval through two 
IRB’s. 
Recruit subjects to the 
study, and complete 
first visit (two groups 
of 20 for three 
months) 
Patient were 
identified from POCT 
labs done in office 
1/1/2013 to 7/30/2013  
Participants seen at 
follow up visits 
Participants seen at 1 
and 2 month follow 
up visits where CGM 
and blood glucose 
2/1/2013 to 9/30/2013  
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testing data was 
obtained. 
Final visit for study  Final data collection 
obtained for all 
participants 







and statistician input 
By 10/15/2013  
Presentation of 
capstone to committee 
Final presentation 12/6/13  
 
 
Resources – Personnel, Technology, Budget 
Costs Associated with the Study 
 There were a number of direct and indirect costs associated with this study.  The 
Medtronic Guardian continuous glucose monitors and Enlite sensor was provided by a grant 
from Medtronic.  Other costs associated with the study included HbA1c levels done at baseline 
and 3 months for all 21 participants.  Nursing time for each participant to teach the CGM device 
was estimated at 1.5 hours for each participant starting into the study.   The investigators time 
and medical assistant’s time to download the monitors were donated by the Department of 
Pediatrics and were not calculated into the costs of the study. The study also provided lidocaine / 
prilocaine cream free of charge for each of the participants to decrease the pain associated with 
the insertion of the CGM sensor.  The study also budgeted a nominal amount for the investigator 
to travel to a meeting to disseminate the research findings. (Appendix D) 
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 Sources of Study Funding 
 The majority of the funding for indirect costs for the study was provided in the form of 
grant for study supplies from Medtronic. Medtronic Diabetes approved a grant for the Guardian 
Continuous Glucose Monitoring System, Enlite CGM sensors and sensor inserters for 21 of the 
participants. The funding to cover HbA1c levels, patient visit incentive and incidentals came 
from the Charleston Area Medical Center Research Fund.  
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CHAPTER IV RESULTS 
Introduction 
 The goal of this study was to evaluate the effectiveness of continuous glucose monitoring 
(CGM) in children, adolescents and young adults ages 7 to 21 years with poorly controlled type 
1 diabetes (HbA1c level at 9% or greater).  The primary outcomes that were measured included 
glycemic control (HbA1c), adherence to the treatment regimen, hypoglycemia and quality of life. 
Demographics  
 The total number of participants recruited into the study who completed the baseline 
study visit was 33.  A total of 21 participants completed the final study visit.  Demographics for 
the population were described in Table 2-8.  The study had an attrition rate of 36.4%.  The 
reasons for attrition were as follows:  one was not able to complete the visits due to family 
illness, two reported skin irritation from the adhesive tape on the glucose sensor, and the other 
nine did not continue because they did not wish to continue wearing the monitor.  Some of 
participants did not like physically wearing the sensor, while others did not like the alarms from 
high blood glucose readings.   The mean HbA1c of all participants at baseline was 10.515% 
(SD=1.4127) with a range of 9-14%.  The mean age of all participants was 15.42 years 
(SD=2.750) with a range of 9-20 years.  There was no difference in age (p=0.691), duration of 
diabetes (p=0.698), HbA1c (p=0.655) or weight (p=0.351) between the group that started the 
study and those that completed the study.  Of the 21 that finished the study, 47.6% were male 
and 52.4% were female, 95.2% were Caucasian and 4.8% were African American.  The ages of 
the group that finished the study ranged from 11 to 20 years of age with the mean being 15.57 
(SD=2.657).  Household demographics showed 57.1% of the subjects lived in a two parent 
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household, 14.3% lived with their mother only, 9.5% lived with their father, 4.8% lived with 
grandparents, and the remaining 9.5% either lived by themselves or with a significant other.  
Quality of life questionnaires were completed by 100% of the participants who completed the 
final study visit.    
Demographics  




 Frequency Percent 
 
Male 10 47.6 
Female 11 52.4 
Total 21 100.0 
 
Table 3  
Race  
 Frequency Percent 
 
Caucasian 20 95.2 
African American 1 4.8 




Other Reported Health Conditions 
 
 Frequency Percent 
 
None 14 66.7 
Addison disease 1 4.8 
Celiac, hypothyroid 1 4.8 
Depression 1 4.8 
Hypertension 1 4.8 
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Hypothyroid, Cholestero 1 4.8 
Hypothyroid, HTN 1 4.8 
Microalbuminuria 1 4.8 
Total 21 100.0 
 
Table 5  
Insulin Delivery Method 
 Frequency Percent 
 
Injections 9 42.9 
Pump 12 57.1 
Total 21 100.0 
 
Table 6  
Primary Caregiver 
 Frequency Percent 
 
Mother 15 71.4 
Father 2 9.5 
Grandparent 1 4.8 
Extended family 1 4.8 
Other 2 9.5 
Total 21 100.0 
 
 
Table 7  
Family Description 
Lives with Frequency Percent 
 
Mother 3 14.3 
Father 2 9.5 
Both parents 12 57.1 
Grandparent 1 4.8 
Other 3 14.3 
Total 21 100.0 
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Table 8  
Baseline Descriptive Statistics Of Subjects that Completed Study 
 
 N Minimum Maximum Mean Std. Deviation 
Age 21 11 20 15.57 2.657 
Age at Diagnosis 21 2 17 7.86 3.890 
Years With Diabetes 21 1 17 7.74 4.200 
HBA1c  21 9.0 14.0 10.600 1.4900 
BG daily test reported 21 2.0 9.0 4.214 1.7859 
BG test from meter 21 .0 6.6 2.686 1.8610 
Insulin TDD 21 .56 1.75 1.0431 .28858 




 The mean baseline HbA1c of the participants completing the study was 10.600% 
(SD=1.49) with a range of 9-14%. The mean HbA1c at completion of the study was 9.490% 
(SD=1.47) with a range of 7.3-12.3%.  This was a statistically significant HgbA1c improvement 
of 1.1095% (SD=1.9321) p=0.016.  The change in HbA1c ranged from an improvement of 6.7% 
to worsening of 2.5%.   
Significance of improvement 
Seventeen of the 21 participants demonstrated an improvement in HbA1c.  The 
improvement in glycemic control ranged from 0.1% to 6.7%. Two of the participants had 
improvements of less than 0.5%. Fifteen of the participants had clinically significant 
improvement in HbA1c >0.5%. Eleven of the participants had an improvement between 0.5 and 
2%.  Four of the participants had an improvement of greater than 2%.  The mean weight in the 
group increased by 1.4134kg (SD=2.7263) p=0.026.   
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Participants without improvement 
Of the four participants who had a worsening HbA1c, two of these participants admitted 
to manipulation of the CGM device. One of the participants admitted at the final visit to entering 
false lower blood glucose values in the CGM to get the monitor to read lower blood glucose 
readings.  The other participant admitted to not testing blood glucose values and entering 
fictitious readings into the monitor to keep the CGM reading.  The HbA1c levels were 
recalculated removing these two subjects and a statistically significant reduction in mean 
HgbA1c remained. After exclusion of these subjects the mean baseline HbA1c was 10.668% 
(SD=1.5532) and improved at final visit to 9.211% (SD=1.2490).  The mean improvement of 
HbA1c was therefore 1.4579% (SD=1.6711) p=0.001. 
Adherence 
Adherence was tracked at each visit and at the final visit.  Home blood glucose meters 
were downloaded at each visit and participants also self-reported the number of times per day 
they were testing blood glucose values.  Participants self-reported testing their blood sugars 
4.214 (SD=1.7859) times a day at baseline with a range of 2-9 times per day.  This increased to 
4.3095 (SD=2.01542) at visit two and up to 4.342 (SD=2.3336) at visit 3 and slightly down to 
4.071 (SD=2.4763) at the final visit.  Therefore, a significant difference in self-reported glucose 
testing was not demonstrated. Blood glucose monitors were downloaded at each visit and the 
baseline mean number of actual tests per day was 2.686 (SD=1.8610) with a range of 0 to 6.6.  
The mean increased to 3.781 (SD=2.5459) times per day at visit two, then declined to 3.284 
(SD=2.2877) at visit three and down to 2.738 (SD=2.6447) at the final visit.  There was no 
significant difference in number of blood glucose tests reported by the participants (p=0.745) or 
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actual (p=0.121) blood glucose values that were downloaded from the participant’s blood 
glucose meter at each visit. When comparing reported number with actual blood glucose testing, 
there was significant difference in the number of tests reported versus actual at the baseline visit 
(p=0.000), visit three (p=0.017) and the final visit (p=0.006).  There was no difference between 
the number reported and actual download at visit 2 (p=0.137). 
Participants wore the CGM monitor for a mean of 51.14 days (SD=20.865) with a range 
of 20 to 81 days.  The mean number of total hours the CGM was worn by participants was 
820.4286 (SD=437.58423) with a range of 386 to 1674 hours.  The mean sensor reading for the 
study was 211.05 mg/dL (SD=34.683).  There was no correlation between duration of sensor use 
and HbA1c improvement (p=0.822).  There was no difference in reported total daily dose of 
insulin given at each of the visits (p=0.944).  Participants were given a diary to complete for 
family meetings, significant hypoglycemia, and reasons for not wearing the CGM monitor.  Only 
two out of the 21 diaries were returned so analysis of the diary data was not possible. None of the 
participants required/requested topical lidocaine / prilocaine cream for ease of CGM sensor 
insertion. 
Hypoglycemia 
 Hypoglycemia was monitored by self-report at follow up visits and by analysis of CGM 
data download.  One participant reported having a clinically significant hypoglycemic episode 
that required assistance to correct.  This participant had two episodes within one week; the 
episodes were described as “passing out”.  Hypoglycemia was treated successfully with oral 
glucose and the participant did not require hospital emergency treatment.  When reviewing the 
episodes with the participant, they both occurred when the participant was not wearing the 
continuous glucose monitor.  The percentage of time the CGM area under the curve < 70 mg/dL 
Running head: Effectiveness of Continuous Glucose Monitoring 40 
 
was 0.500 % (SD=0.5030) with a range from 0 to 1.9%.  None of the time spent in hypoglycemia 
episodes reported by the CGM monitor require assistance to correct.   
Quality of life  
 All participants that completed the final study visit completed all questions in the Quality 
of Life in Diabetes Youth Short Form questionnaire.  The questionnaire includes six subsets that 
impacted diabetes.  A higher number in each area is associated with worsening impact. The 
baseline mean of symptoms was 4.24 (SD=0.497) and improved to 3.67 (SD=0.532) at the final 
visit p=0.319.  The baseline mean for treatment was 3.05 (SD=2.062) and improved to 2.43 
(SD=2.378) at the final visit p=0.242.  The baseline mean for activities was 2.76 (SD=3.419) and 
worsened to 3.76 (SD=4.657) at the final visit p=0.144.  The baseline mean for parental impact 
was 6.48 (SD=3.459) and improved to 5.62 (SD=4.153) at the final visit p=0.204.  The baseline 
mean for worry was 8.29 (SD=6.908) and improved to 7.10 (SD=7.063) at the final visit 
p=0.258.  The baseline mean for health was 2.71 (SD=0.845) and improved to 2.48 (SD=0.814) 
at the final visit p=0.204.  There was significant correlation for all items except for symptoms.  
There were no statistically significant improvements in quality of life in the six areas measured 
by the questionnaire although improvement was seen in all categories except activities. 
Significance may not have been realized because of the small number of subjects or short 
duration of the intervention. 
Qualitative questionnaire findings 
Qualitative Data Analysis: 
 Qualitative data were collected at each of the follow up visits.  Participants were asked if 
they met on a regular basis to review and discuss the use of the continuous glucose monitor.  
Thirteen (61.9%) of the participants responded that they met on a regular basis.  Four (19.0%) 
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reported that regular meetings did not occur. Four (19.0%) of the participants lived on their own 
and did not have parental involvement in order to be able meet for the family meeting.   
Of the thirteen participants who met on a regular basis to discuss glycemic control, self-
reported topics of discussion revealed three major themes.  The first theme identified was 
identification of blood sugar problems that were previously not recognized.  Some of the 
findings reported included: higher blood glucose values at night which were not known, 
hyperglycemia before lunch and dinner, nocturnal hypoglycemia, post-prandial hyperglycemia 
and rebound hyperglycemia.  The second common theme was seeing the CGM monitor catch 
hyperglycemia and hypoglycemia before they occurred.  Participants were able to identify causes 
of glycemic deviation and the reasons the blood glucoses were going low or high at different 
times.  The final common theme was the monitor helped keep them on track.  This included 
noticing how different things affected blood glucose values.  Other issues that were discussed 
included: family reviewing blood sugars, noting that the participant needed to test more 
frequently, and frequent sensor alarms.  The families were instructed to determine consequences 
for participants that did not wear the CGM monitor on a regular basis.  Eleven of the families 
reported that their child was wearing the device on a regular basis and did not require 
implementation of consequences. Two of the participants did not wear the CGM monitor on a 
regular basis, but the families did not implement consequences as directed.  Four of the 
participants were living independently and did not have parental involvement to implement 
consequences.  Two of the participants wore the monitor the majority of the time, but the parent 
did not review the monitor as was discussed in the treatment plan.  These were the two 
participants that had manipulated the CGM to provide readings and because of this manipulation, 
they were not getting accurate readings.   
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 Participants were asked how the CGM monitor helped them at each follow up visit.  Four 
themes were identified during the follow up visits.  The first theme was improved attitude toward 
diabetes.  Parents described the following areas that were related to behavior: improved attitude 
overall, changed attitude toward diabetes, making diabetes more tolerable, and improved interest 
in other activities.  The child parent relationship was described as improved based on the 
following descriptions: added security when the child is away from the parent, parental piece of 
mind at night, decreased parental nagging, and improved mother/daughter relationships.  The 
participants state that they feel better while wearing the CGM.  They described this with the 
following: feels better now that blood sugar is better, knowing what blood sugar is all of the 
time, insulin is given more frequently because of increased awareness, it demonstrates how 
different foods affect the blood sugar, it helps understand how the blood sugar affects the way 
she feels, and they are watching things closer.  The participants and parents also felt that the 
alarms were helpful to prevent low blood sugars with the predictive alarm, and to treat higher 
blood sugars quicker so they don’t stay as high for as long. 
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CHAPTER V SUMMARY, DISCUSSION, IMPLICATIONS 
Congruence with Theoretical Framework 
 The Family Approach to Diabetes Management is a behavior modification program 
developed to bring families together to encourage children with diabetes to complete the basics 
of self-care to improve their self-management skills.  This project uses basic concepts of the 
framework to involve the family in encouraging the participant to wear the CGM monitor.  Past 
studies have shown improvement in HbA1c when the CGM sensor is worn for 6 or more days a 
week.  All participants and families were trained in the basics of FAMD model at the study 
initiation visit and encouraged to utilize the concepts they had been taught at each follow up 
visits.  Eleven of the families reported meeting on a regular basis and encouraged the participant 
to wear the sensor on a regular basis.  Four of the participants were living on their own and were 
encouraged to have their close support system stress for them to wear the CGM monitor.  Two of 
the participants wore the monitor on a consistent basis, however they manipulated the CGM data 
by entering in erroneous blood sugars that caused the monitor to provide false data.  This shows 
that family involvement is essential to keep the adolescent on track and using the monitor 
correctly.   
 The FADM model can be successfully implemented into an outpatient clinic environment 
to help improve the outcomes of adolescents with diabetes.  The model can be used to help 
encourage regular use of the CGM monitor.  With proper presentation and integration into 
clinical practice, the FADM model can be seen by the child, adolescent or young adult not as a 
punishment, but as an encouragement and expectation to strive to improve their self-care 
behaviors.  The parents in this study either fully supported the use of the CGM and reported the 
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patient wore the monitor all of the time, or the patients were left to monitor their own self-care.  
The parents that were not active in their patient’s care during the study reported they were going 
to use the model after their last study visit to improve the self-care deficits that were identified in 
the study.  
Discussion 
HbA1c 
 There was a clinically and statistically significant improvement in HbA1c of 1.1095% 
(SD=1.9321) p=0.016 during the 12 week study.  At the end of the study, two participants were 
identified as manipulating the CGM device and did not provide accurate finger stick blood 
glucoses to calibrate the monitor.   The change in HbA1c was recalculated after removing these 2 
participants from the analysis and there was outliers a mean improvement of 1.4579% 
(SD=1.6711) p=0.001.  The studies that were identified from the literature search had HbA1c 
levels that ranged from no improvement to an improvement of 1% (Battelino et al., 2011; Raccah 
et al., 2009; Joubert & Reznik, 2011; Wojciechowski, Ryś, Lipowska, Gawęska, & Małecki, 
2011). For this study an improvement of 0.5% was considered clinically significant.  Fifteen of 
the participants (71.4%) had an improvement of greater than 0.5% in HbA1c.  Eleven of the 
participants had final HbA1c levels that improved to less than 9%.  Two of those participants had 
final HbA1c levels in the 7% range.  A HbA1c of less than 8% is considered in goal for this age 
group (Silverstein et al., 2005). While not all participants had improvement in HbA1c, those that 
had clinically significant improvement in glycemic control ranged from 0.8 % to 6.7%.  While 
the mean improvement of HbA1c was greater than the other studies that were reviewed, the 
baseline HbA1c was higher in this study, and therefore had more potential to improve.  With 
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intensification of glycemic control, there is risk of weight gain.  The participants had a mean 
weight gain of 1.4134kg (SD=2.7263) p=0.026, while the weight gain is statistically significant, 
it is not a clinically significant increase. 
Adherence 
 Participants wore the CGM monitor a mean of 51.1429 (SD=20.68543) days with a range 
of 21 to 81, for this study wearing the monitor any part of the day was considered as a day for 
analysis.  Participants wore the monitor a mean of 4.262 days a week.  The previous JDRF study 
found improvement in Hba1c when the CGM monitor was worn 6 or more days a week (Beck et 
al., 2009a).  In this study there was no correlation with duration of use of the CGM and the 
improvement in HbA1c (Pearson Correlation 0.334) p=0.162.  There was no significant change 
in number of blood sugar tests (testing reported or actual) during the intervention.  The study 
goal was to increase the average number of blood glucose tests to an average 3 tests per day.  
This goal was met at follow up visits two and three; however the mean number of test fell below 
3 per at the final visit. The number of actual tests decreased close to baseline by the final visit.  
One concern was that the participants would test less with the monitor and rely on the readings 
of the CGM to dose insulin rather than on their home glucose monitor.  A significant decrease in 
home blood sugar testing was not found to happen during this study.   
Hypoglycemia 
 None of the participants reported having clinically significant hypoglycemia while 
wearing the monitor.  Significant hypoglycemia is defined as requiring another person to help 
treat the hypoglycemia.  This does not include symptomatic hypoglycemia that the participants 
were able to self-treat and correct on their own.  Although, one participant reported report having 
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two clinically significant hypoglycemia events during the study, the participant was not wearing 
the CGM monitor when he had the events.  The CGM downloads reports showed the participants 
had blood sugars of <70 mg/dl a mean of 0.5% (SD=0.5030) of the total time the CGM was 
worn with a range from 0 to 1.9%.  None of the recorded time in hypoglycemia on the CGM 
monitor was report as being clinically significant by the participants.  Previous studies showed 
less hypoglycemia in groups wearing CGM compared to the control groups without CGM 
therapy (Battelino et al., 2011; Beck et al., 2009b).  Wearing the CGM in combination with 
improving glycemic control does not appear to be associated with self-reported clinically 
significant hypoglycemia.  These findings are similar to those reported in previous studies.  
Nevertheless, participants with improved glycemic control need to be aware of increased risk of 
hypoglycemia and should monitor their blood glucose and symptoms very closely. 
Quality of life 
 While there were no significant differences in quality of life among the six areas 
evaluated, two areas - parental impact and worry about diabetes - had overall higher scores than 
symptoms, treatment, activities and health.   There was a trend in improvement of areas of 
symptoms, treatment, parental issues, worry, and health.  The areas related to activities worsened 
from the baseline visit.  While these trends were identified, none of the changes were statistically 
significant.  The highest area reported was in worry about diabetes.  These areas related to future 
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Qualitative findings 
 A majority of families (61.9%) met on a regular basis to discuss the CGM monitor and 
the blood sugars.  The families that met identified a number of blood glucose problem areas.  
They also were able to discover blood glucose problems that were not previously identified or 
known.  All of the families had been instructed on use of the FADM model.  The participants 
that did not wear the monitor on a regular basis did not have any consequences or penalties put in 
place for poor behavior.  The two participants that manipulated the CGM data were the ones that 
the family did meet with their child to review the monitor on a regular basis. The families and 
participants found the monitor to be helpful in a number of areas.  Those that were expected 
included more frequent dosing of insulin and detection of high and low blood sugars.  The areas 
that were reported and not expected were improved attitude and improved parent interaction. 
Significance 
 This study offers evidence that continuous glucose monitoring improves glycemic control 
in children, adolescents, and young adults with poorly controlled diabetes with a HbA1c > 9.0%.  
This was a short-term 12-week intervention, so it is not known if there would be further 
improvement or regression of glycemic control with long-term continual use of CGM.  The 
attrition rate for the study was high, and so future interventions should include focusing on 
improving retention rates in this difficult population. This intervention requires additional daily 
activities beyond what the participants had been doing and it may be more work than they are 
willing to do.  It is possible for participants to manipulate the CGM monitor; close attention 
needs to be paid to participants whose family does not meet on a regular basis to monitor their 
child’s care.  Previous studies found improvement in glycemic control when the CGM monitor 
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was worn 6 or more days a week.  This study showed improvement in HbA1c when the mean 
number of days of CGM was about 4.2 days per week.  Although there was improvement of 
HgA1c in this study, this improvement was not correlated with duration of CGM use.  While 
there was one participant that reported significant hypoglycemia during the study, this happened 
when the participant was not wearing the CGM sensor.  There was no clinically significant 
hypoglycemia reported when the participants were wearing the monitor.   
Practice recommendations 
 Prior to this practice change project, CGM use was limited to request by patient or by 
recommendation for patients that had significant hypoglycemic events.  The project findings 
showed that CGM can be successfully implemented in a clinical practice.  We are now offering 
CGM monitoring to all patients who are not at goal of HbA1c and who have third party payer 
coverage for the system.  Of the twenty-one participants that completed the study, four of the 
participants now have their own CGM monitors.  There are a number of clinic patients that were 
not in the study that have been started on CGM monitors.  While CGM monitoring is being 
implemented into our clinic, there is still a limitation with third party coverage, particularly 
Medicaid, Chips and West Virginia PEIA.  That data from this practice change project will be 
used to work with these payers to expand coverage to this vulnerable population.   
Conclusions 
 CGM with the FADM model was effective in improving glycemic control with children, 
adolescents and young adults with poorly controlled diabetes. There was a small but significant 
increase in weight during the intervention.  There was no significant change in total daily dose of 
insulin reported, adherence with blood sugar testing or quality of life during the intervention.  
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There was no clinically significant hypoglycemia reported during the CGM monitor use.  
Qualitative data analysis revealed the participants and their families had improvement in attitude 
toward diabetes and improved parent child interactions. 
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Evidence of Key Site Support (Appendix A) 
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Continuous Glucose Monitoring Data Collection Tool (Appendix B) 
 
Patient ID: ________________ 
Age: _______________ 
Gender: Male ___ Female ____ 
Pubertal Status: Pre ___ Post _____ 
Other health conditions: 
___________________________________________________________________ 
Age at diagnosis ________ 
Number of years with diabetes: ___________ 
Lives with: Mother _____ Father _________ Grandparent ___________ Extended Family 
____________ Other: _________________ 
 
Baseline Visit Data: 
HbA1c Level: _____________% 
Reported number of blood sugar tests per day: ______ Actual from meter: ____________ 
Total Insulin Dose reported given per day ________ units/kg/day 
Quality of Life tool completed: ______ 
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Visit 2 Data (one month): 
Reported number of blood sugar tests per day: ______ Actual from meter: ____________ 
Total Insulin Dose reported given per day ________ units/kg/day 
Reports of Severe hypoglycemia requiring assistance: _______ number of events: ____ 
 
Visit 3 Data (two months): 
Reported number of blood sugar tests per day: ______ Actual from meter: ____________ 
Total Insulin Dose reported given per day ________ units/kg/day 
Reports of Severe hypoglycemia requiring assistance: _______ number of events: ____ 
Final Visit Data (three months): 
HbA1c Level: _____________% 
Reported number of blood sugar tests per day: ______ Actual from meter: ____________ 
Total Insulin Dose reported given per day ________ units/kg/day 
Reports of Severe hypoglycemia requiring assistance: _______ number of events: ____ 
Quality of Life tool completed: ______ 
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 Qualitative data collection tool patients: (Appendix C) 
























Are there any problems you are having with the system? 
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Capstone Budget (Appendix D) 
 
BUDGET FOR CONDUCTING STUDY 
Effectiveness of Continuous Glucose Monitoring in Children and Adolescents 
With Poorly Controlled Type 1 Diabetes 
 
PLEASE ITEMIZE IN DETAIL THE ESTIMATED COSTS TO CONDUCT THIS STUDY.  
DIRECT COSTS      Requested     
 Medtronic 
Funds    Donated Costs  
PERSONNEL 
Consultants/Temporary 
    (Hourly rate x # of hrs)    $__________   $__________  
Consultants/Temporary      
    (Hourly rate x # of hrs)    $__________   $__________  
Consultants/Temporary 
    (Hourly rate x # of hrs)    $__________   $__________  
 
Other Contractual Services    $__________   $__________  
 
NON-PERSONNEL 
Space Rental Charges    $__________   $__________  
 
Equipment  
Item #1 (Cost + tax)  CGM Monitor  $__________   $__25980___  
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Item #2 (Cost + tax)     $__________   $_____  
 
Supplies 
Item #1 (Unit cost + tax) CGM Sensors  $__________  
 $__36000________ 
Item #2 (Unit cost + tax)    $__________   $__________ 
 
Miscellaneous 
Telephone Costs     $__________   $__________ 
Printing Costs (# x cost per item)   $__________   $__________ 
Copier Costs      $__________   $__________ 
Copy Paper      $__________   $__________ 
Postage/Fed. Ex     $__________   $__________ 
Software Costs      $__________  
 $__________  
Slides for presentation    $__________   $__________ 
Other (list each item)     $__________   $__________ 
 
Patient Care Costs 
Pharmacy/Drugs     $__1000_____  
 $__________ 
Laboratory       $___656______  
 $__________ 
Lab #1       $__________   $__________ 
Lab #2       $__________   $__________ 
Patient Reimbursement     $___3200_____  
 $__________ 




Travel Related to study conduct   $__________   $__________ 




TOTAL COSTS REQUESTED    $__6356_____    
TOTAL COSTS DONATED        $ _61980___ 
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Agreement for us of Quality of Life Tool (Appendix E) 
 
